Caricamento...
Selective use of vandetanib in the treatment of thyroid cancer
Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyro...
Salvato in:
| Pubblicato in: | Drug Des Devel Ther |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498730/ https://ncbi.nlm.nih.gov/pubmed/26170630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S72495 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|